University of Kentucky Alzheimer's Disease Core Center - Biomarker Core

摘要 肯塔基大学阿尔茨海默氏症中心(UK-ADC)成立于1985年，在 不断扩大规模和范围的生物标记物倡议的出现。我们建议开发一种 BioMarker Core以丰富英国-ADC并提供基础设施，使我们能够做出重大贡献 生前生物标记物的发现。英国-ADC的重点是从正常的早期过渡 认知老化对认知功能障碍的发展。广告领域的焦点转移到更早、更早的 疾病的临床分期是我们中心的理想定位，我们的中心一直专注于认知正常的受试者 以及早期检测和跟踪过去30年与退行性疾病状态相关的变化。 因此，我们的中心已经收集了700多个血浆样本，100个脑脊液样本和250个磁共振电池。 认知完好的个体。此外，我们有超过350个血浆样本，150个脑脊液样本和300个核磁共振 由轻度认知障碍患者提供的电池。在建立生物标记核心的过程中，我们将建立一个 使我们能够分析、分发和跟踪这些有价值的当前和未来生物标记物的基础设施 样本。基础设施还将为我们提供支持校内、校外和国家的手段 生物标记物倡议，如NACC、ADGC/NCRAD、ADNI、ADCS/ATRI和其他NIH/NIA倡议。我们会 还建立了一个可供试验的、以生物标记物为特征的受试者队列，促进了进入校内和 校外临床转化研究，以消除招募和筛选失败的瓶颈。最后，我们的中心 一直处于AD模拟物研究的前沿，包括海马硬化症(HS-Aging)，初级年龄- 相关的肌萎缩侧索硬化症(部分)，与大脑年龄相关的TDP-43和硬化症(CART)，以及对血管的贡献 认知障碍和痴呆(VCID)。因此，增加一个生物标志物核心将使我们能够继续 为这些领域做出贡献，并对这些领域的生物标记物开发迅速增长的兴趣。总的来说， 对我们新的生物标记核心的支持将使我们能够增加所需的基础设施来支持 NIH/NIA的倡议和我们的研究人员在21世纪及以后的需求。

ABSTRACT The University of Kentucky Alzheimer's Disease Center (UK-ADC) was founded in 1985, prior to the advent of biomarker initiatives that continue to grow in size and scope. We propose the development of a Biomarker Core to enrich the UK-ADC and provide an infrastructure that will allow us to contribute significantly to the discovery of antemortem biomarkers. The UK-ADC has focused on the early transitions from normal cognitive aging to the development of cognitive impairment. The shift of focus in the AD field to earlier, pre- clinical stages of disease ideally positions our center, which has had a focus on subjects with normal cognition and early detection and tracking of changes associated with degenerative disease states for the last 30 years. As a result, our center has collected over 700 plasma samples, 100 CSF samples, and 250 MRI batteries from cognitively intact individuals. Further, we have over 350 plasma samples, 150 CSF samples and 300 MRI batteries from individuals with mild cognitive impairment. In establishing a biomarker core, we will build an infrastructure that allows us to analyze, distribute and track these valuable current and future biomarker samples. The infrastructure will also provide the means for us to support intramural, extramural, and national biomarker initiatives such as NACC, ADGC/NCRAD, ADNI, ADCS/ATRI and other NIH/NIA initiatives. We will also establish a trial-ready, biomarker-characterized, subject cohort, facilitating enrollment into intramural and extramural clinical translational studies to eliminate recruitment and screen fail bottlenecks. Finally, our center has been at the forefront of research on AD-mimics including hippocampal sclerosis (HS-Aging), primary age- related tauopathies (PART), cerebral age-related TDP-43 and sclerosis (CARTS), and vascular contributions to cognitive impairment and dementia (VCID). As such, the addition of a biomarker core will allow us to continue to contribute to these fields and the rapidly growing interest in biomarker development in these areas. Overall, the bolus of support for our new biomarker core will allow us the increased infrastructure needed to support NIH/NIA initiatives and our researchers needs in the 21st century and beyond.